Pancreatic Cancer Research

ResearcherCentral South UniversityNo recent work listed

Hai Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0005-2229-8148; OpenAlex author ID A5100452503. Sources: OpenAlex.

Their work

Papers
7 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
22
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: 1 paper · 2018: none · 2019: 2 papers · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper

Papers 7

  1. SLC1A5 Prefers to Play as an Accomplice Rather Than an Opponent in Pancreatic Adenocarcinoma. First author DOI 10.3389/fcell.2022.800925↗
  2. CYP2J2-produced epoxyeicosatrienoic acids contribute to the ferroptosis resistance of pancreatic ductal adenocarcinoma in a PPARγ-dependent manner. Co-author DOI 10.11817/j.issn.1672-7347.2021.210413↗
  3. Inhibition of LONP1 protects against erastin-induced ferroptosis in Pancreatic ductal adenocarcinoma PANC1 cells. Co-author DOI 10.1016/j.bbrc.2019.11.187↗
  4. Potential use of aptamers for diagnosis and treatment of pancreatic cancer. Co-author DOI 10.1080/1061186x.2018.1564924↗
  5. Inhibition of LONP1 Suppresses Pancreatic Cancer Progression Via c-Jun N-Terminal Kinase Pathway-Meditated Epithelial-Mesenchymal Transition. First author DOI 10.1097/mpa.0000000000001321↗
  6. Photothermal Effect Enhanced Cascade-Targeting Strategy for Improved Pancreatic Cancer Therapy by Gold Nanoshell@Mesoporous Silica Nanorod. Co-author DOI 10.1021/acsnano.7b02918↗
  7. Co-delivery of HIF1α siRNA and gemcitabine via biocompatible lipid-polymer hybrid nanoparticles for effective treatment of pancreatic cancer. Co-author DOI 10.1016/j.biomaterials.2014.12.028↗

Closest collaborators

The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ge Gao · 3 shared papers, 2019–2021 · strength 0.39
  2. Can Liu · 2 shared papers, 2019–2020 · strength 0.20
  3. Yong Zhou · 2 shared papers, 2019–2020 · strength 0.20
  4. Pengzuo Tao · 1 shared paper, 2021 · strength 0.19
  5. Bincheng Ren · 1 shared paper, 2022 · strength 0.16
  6. Fangshi Xu · 1 shared paper, 2022 · strength 0.16
  7. Zhengliang Zhang · 1 shared paper, 2022 · strength 0.16
  8. Honghong Pei · 1 shared paper, 2022 · strength 0.16
  9. Yiye Li · 2 shared papers, 2015–2017 · strength 0.13
  10. Guangjun Nie · 2 shared papers, 2015–2017 · strength 0.13
  11. Can Liu · 1 shared paper, 2019 · strength 0.11
  12. Juewen Liu · 1 shared paper, 2019 · strength 0.11
  13. Ge Gao · 1 shared paper, 2019 · strength 0.11
  14. Xiang Wu · 1 shared paper, 2019 · strength 0.09
  15. Gary Guishan Xiao · 1 shared paper, 2019 · strength 0.09
  16. Ruifang Zhao · 1 shared paper, 2017 · strength 0.08
  17. Tianjiao Ji · 1 shared paper, 2017 · strength 0.08
  18. Yuliang Zhao · 1 shared paper, 2017 · strength 0.08
  19. Jing Chen · 1 shared paper, 2015 · strength 0.05
  20. Xiao Ling Zhao · 1 shared paper, 2015 · strength 0.05
  21. Jihui Hao · 1 shared paper, 2015 · strength 0.05
  22. He Ren · 1 shared paper, 2015 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.